Tango Therapeutics downgraded by Jefferies with a new price target
Stocks in this Quantisnow insightHealth Care
Historical context for TNGX
Across the 19 sessions after earlier TNGX headlines, the stock closed higher 9 times and lower 9 times, with a median move of 3.0% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | TNGX | SPY |
|---|---|---|---|
| May 14, 2026 | Tango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights | -2.5% | +0.8% |
| May 5, 2026 | Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | +6.6% | +0.8% |
| Apr 15, 2026 | Tango Therapeutics Announces Leadership Appointments to Accelerate Late-Stage Development of Vopimetostat | +5.3% | +0.8% |
| Apr 6, 2026 | Canaccord Genuity initiated coverage on Tango Therapeutics with a new price target | -6.2% | +0.5% |
| Apr 2, 2026 | Canaccord Genuity initiated coverage on Tango Therapeutics with a new price target | +1.9% | +0.1% |
| Mar 9, 2026 | Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | -2.9% | +0.9% |
Quantisnow market dataNASDAQ
TNGX
Tango Therapeutics Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2020
Get push alerts for TNGX
Full TNGX profile on Quantisnow Follow TNGX and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time